UPCOMING SESSIONS in ET
Thu, Jul 2, 2026
5:00 – 6:00 AM Bangkok
Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis Michael Rosenzweig Click To Register
UPCOMING SESSIONS in ET
Thu, Jul 2, 2026 · 5:00 – 6:00 AM Bangkok
Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis
Michael Rosenzweig
Click To Register
View all sessions

Systemic Amyloidosis

Published: Jul 30, 2026
Key Information
Source
Saygı Hastanesi
summary/abstract

Systemic amyloidosis (ICD-10: E85.4) is multiorgan dysfunction syndrome from extracellular amyloid fibril deposition (AL, ATTR, AA). Features include cardiac (heart failure, restrictive cardiomyopathy), renal (proteinuria, nephrotic syndrome) and neurologic involvement. ISA 2024 and ESC 2023 HF guidelines recommend bone scintigraphy (DPD/PYP), free light chains and tissue biopsy. Daratumumab+CyBorD for AL; tafamidis and vutrisiran for ATTR.